Mr Grover will be delivering a presentation at the BRSS on a research project: “Enhancing the treatment pathway for benign intracranial tumours through AI.”
Representatives from our medical team at Amethyst Radiotherapy have made valuable contributions to talks and discussions at the annual meeting of the British Radiosurgery Society (BRSS), which took place in Birmingham on 23-24 January.
We were also proud to be sponsoring this highly regarded conference, where the most cutting-edge advancements in the field of brain cancer research and treatment will be discussed. On 23 January, Mr Patrick Grover delivered a presentation on a research project: “Enhancing the treatment pathway for benign intracranial tumours through AI.”
Here’s an overview of how artificial intelligence (AI) might be used in the future to assist with the treatment of large-size metastases.
There are already various AI tools in use to assist with advanced image analysis of magnetic resonance imaging (MRI) and computed tomography (CT) scans, which are the most commonly used type of scan for the diagnosis of large-size metastases. This allows for much greater accuracy than would be possible through human labour alone.
AI technology has the potential to identify different types of tumour with more precision, and is capable of distinguishing subtle changes that may be missed by the human eye. This means that tumours can be detected at an earlier stage, enabling the most appropriate treatments to be started before the tumour grows larger or spreads.
The greater accuracy of AI diagnostic tools means that more effective personalised treatment plans can be put in place. Furthermore, AI techniques could potentially be used to create individual treatment plans based on the genetic characteristics of the patient.
AI powered tools are already in use to assist surgeons in several ways. One of the most commonly used methods includes intraoperative guidance, where smart assistants monitor the surgical process, and alert the surgeon to any unforeseen changes.
This reduces the risk of inaccuracies or complications arising during delicate neurosurgery procedures, where the edges of large-size metastases are not always clearly defined.
For radiosurgery and stereotactic radiosurgery such as Gamma Knife surgery, AI tools may be used to map out the tumour locations and boundaries with much more detail and precision.
This enables the tumour cells to be targeted with the light rays with an even greater degree of accuracy, ensuring the maximising amount of radiation is focused on malignant cells, and minimising the risk of damage to the surrounding healthy cells.
AI tools can be involved in patient prognostics, including the monitoring of treatment plans, and the use of patient data to predict the likelihood that the tumour may recur, or in more advanced cases, give the predicted lifespan of the patient.
This enables the medical team to put the most appropriate treatment plan in place, and also allows the patient and their families to prepare themselves better for likely future outcomes.
Centres of Excellence for Stereotactic Radiosurgery treatment of complex Brain Tumours
Want to know more about Gamma Knife Treatment?
Our friendly staff are here to help you, get in touch with them today
